Abstract
Background:
Little is known about the differences between standard-dose statins effects on glucose level and lipids in Japanese patients with diabetes mellitus (DM).
Methods and results:
The 1,049 patients were randomly assigned to either the rosuvastatin group or atorvastatin group. There were no significant differences between the 2 groups in the effect on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c at 12 months. However, physicians tended to switch to more intensive therapy for DM in the atorvastatin group.
Conclusions:
Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels.
Trial registration:
ClinicalTrials.gov NCT01544309.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Asian People
-
Atorvastatin
-
Blood Glucose / metabolism*
-
Cholesterol, HDL / blood
-
Diabetes Mellitus* / blood
-
Diabetes Mellitus* / drug therapy
-
Dose-Response Relationship, Drug
-
Female
-
Fluorobenzenes / administration & dosage*
-
Follow-Up Studies
-
Glycated Hemoglobin / metabolism
-
Heptanoic Acids / administration & dosage*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
-
Hypercholesterolemia* / blood
-
Hypercholesterolemia* / drug therapy
-
Japan
-
Male
-
Pyrimidines / administration & dosage*
-
Pyrroles / administration & dosage*
-
Rosuvastatin Calcium
-
Sulfonamides / administration & dosage*
Substances
-
Blood Glucose
-
Cholesterol, HDL
-
Fluorobenzenes
-
Glycated Hemoglobin A
-
Heptanoic Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Sulfonamides
-
hemoglobin A1c protein, human
-
Rosuvastatin Calcium
-
Atorvastatin
Associated data
-
ClinicalTrials.gov/NCT01544309